China Meheco Group Co Ltd
SSE:600056
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.58
12.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
China Meheco Group Co Ltd
EPS (Diluted)
China Meheco Group Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Meheco Group Co Ltd
SSE:600056
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-6%
|
|
|
COSCO SHIPPING Development Co Ltd
SSE:601866
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
-36%
|
CAGR 5-Years
0%
|
CAGR 10-Years
29%
|
|
|
Xiamen C&D Inc
SSE:600153
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-6%
|
|
|
S
|
Shanxi Coal International Energy Group Co Ltd
SSE:600546
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
-48%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Sichuan New Energy Power Co Ltd
SZSE:000155
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
-8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
C
|
CITIC Metal Co Ltd
SSE:601061
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
China Meheco Group Co Ltd
Glance View
China Meheco Group Co., Ltd., established in 1984, stands as a prominent player in the Chinese pharmaceutical and healthcare sector. As the company evolved over the decades, it navigated the complex Chinese market by strategically positioning itself across the entire pharmaceutical value chain. This involved investing heavily in research and development, securing partnerships with both domestic and international pharmaceutical companies, and streamlining its distribution network to enhance efficiency. Such endeavors have enabled China Meheco to develop and distribute a wide range of medical products, including active pharmaceutical ingredients, finished drugs, medical devices, and traditional Chinese medicines. The company leverages its robust R&D capabilities to continually bring innovative products to market, which has been a significant source of its revenue. China Meheco's business model thrives on its expansive distribution network and strategic collaborations. By aligning with global pharmaceutical giants, the company not only gains access to cutting-edge technologies and advanced formulations but also expands its market reach beyond China. This dual strategy of innovation and partnership ensures a steady flow of products that cater to diverse healthcare needs. Furthermore, China Meheco capitalizes on its local expertise and deep understanding of regulatory frameworks, allowing it to maneuver efficiently within China's complex healthcare landscape. This approach underpins its ability to capture substantial market share in a competitive industry, driving profitability and positioning the company as a key player in the global pharmaceutical arena.
See Also
What is China Meheco Group Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.4
CNY
Based on the financial report for Sep 30, 2025, China Meheco Group Co Ltd's EPS (Diluted) amounts to 0.4 CNY.
What is China Meheco Group Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-6%
Over the last year, the EPS (Diluted) growth was -40%. The average annual EPS (Diluted) growth rates for China Meheco Group Co Ltd have been -3% over the past three years , -21% over the past five years , and -6% over the past ten years .